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Integrative analysis of genomic 
sequencing data reveals higher 
prevalence of LRP1B mutations in 
lung adenocarcinoma patients with 
COPD
Dakai Xiao1,2,3, Fuqiang Li  4,5, Hui Pan1,2, Han Liang4,5, Kui Wu4,5,6 & Jianxing He1,2,3
Both chronic Obstruction Pulmonary Disease (COPD) and lung cancer are leading causes of death 
globally. Although COPD and lung cancer coexist frequently, it is unknown whether lung cancer patients 
with COPD harbor distinct genomic characteristics compared to those without COPD. In this study, we 
retrospectively analyzed genomic sequencing data from 272 patients with lung adenocarcinoma (LUAD) 
and compared the genetic alterations in LUAD patients with and without COPD. Integrative analysis of 
whole-genome and exome sequencing data revealed that COPD and non-COPD groups showed high 
concordance in mutational burden and spectra. Notably, we also found that EGFR mutations were more 
prevalent in LUAD patients without COPD, whereas mutated LRP1B was more frequently observed in 
LUAD patients with COPD. In addition, multi-variable analysis with logistic regression demonstrated 
that mutation of LRP1B was a predictive marker for the presence of COPD in the patients with LUAD. 
Our analysis demonstrated for the first time the high concordance in genomic alterations between the 
tumors from LUAD patients with and without COPD. We also identified higher prevalence of LRP1B 
among the LUAD patients with COPD, which might help understand the underlying mechanisms which 
link COPD and lung cancer.
Chronic Obstruction Pulmonary Disease (COPD) and lung cancer are common lung diseases that coexist fre-
quently. COPD is characterized by progressive airflow obstruction and chronic inflammation in the airways1. 
WHO estimates that COPD will become the third leading cause of death worldwide by 2030.
A number of epidemiological studies have demonstrated that the presence of COPD increased the risk of 
development of lung cancer2–4. Cigarette smoking is considered as a common cause of COPD and lung cancer, 
and the smokers with airflow obstruction are up to 6-fold more likely to develop lung cancer than those with 
normal lung function5. Despite the fact that cigarette smoking is a principal cause of both COPD and lung cancer, 
several population-based studies show that COPD confers the risk for lung cancer regardless of patients’ smoking 
history2, 6–8.
The high prevalence of lung cancer in COPD subjects suggests that there may be certain mechanisms linking 
COPD to lung cancer. In fact, several mechanisms including oxidative stress, genetic predisposition, epigenetic 
modifications and changes in inflammatory milieu and immune defenses, have been proposed to link the patho-
genesis of COPD and development of lung cancer2, 9, 10. Genome-wide association studies (GWAS) have identified 
several single nucleotide polymorphisms (SNPs) which predispose to increased susceptibility to COPD and lung 
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cancer such as SERPIN2, HHIP, FAM13A, IREB2, CHRNA3 and CHRNA52, 11. Other studies also showed that 
inflammatory response factors, aberrant NF-κB activation and cytokine release, and high levels of CD8+ T cells 
mediated the link between COPD and lung cancer12, 13.
It is no doubt that understanding the mechanistic link between COPD and lung cancer would provide ther-
apeutic and preventive benefit for the patients with COPD. However, the molecular mechanisms linking COPD 
with lung cancer development are far from clear, and the heterogeneous nature of lung cancer and COPD made 
it difficult to identify the mechanisms which linked COPD to lung cancer. It is also unknown whether LUAD 
patients with COPD harbor distinct genetic characteristics compared to those without COPD.
In this study, we retrospectively analyzed the genomic sequencing data from 272 LUAD patients, which was 
obtained from our previous study14. We correlated the clinical characteristics with genomic alterations, and 
found the high concordance of genomic alterations in the tumors from LUAD patients with or without COPD. 
Furthermore, we also found EGFR mutations were more prevalent in LUAD patients without COPD, whereas 
mutated LRP1B was more frequently observed in LUAD patients with COPD. To the best of our knowledge, our 
study revealed for the first time the high concordance of genomic alterations in the tumors from LUAD patients 
with COPD and non-COPD at genome-scale. These results also suggested that LUAD patients with COPD hab-
ored distinct somatic alterations in a few genes which can be exploited for personalized medical care for those 
patients.
Results
The clinicopathological characteristics of the LUAD patients with COPD. Among a total of 272 
LUAD patients enrolled in this respective study, 60 subjects (22%) were diagnosed as COPD, and 212 subjects 
(78%) were classified into non-COPD group. As shown in Table 1, Pearson’s chi-square analysis revealed that 
LUAD patients with COPD were significantly associated with male sex, cigarette smoking, older age (64 years 
for COPD Vs 57 years for non-COPD, p < 0.001), and lower value of FEV1, FEV1% and FEV1/FVC (Table 1).
Interestingly, LUAD patients with COPD also exhibited higher Lymphocyte/Monocyte Ratio (LMR) than non-
COPD subjects. However, TNM stage, and counts of neutrophil cells, basophil cells and WBC in the peripheral 
blood did not differ significantly between two groups (Table 1).
The genomic characteristics of LUAD patients with COPD. To explore the genomic alterations asso-
ciated with COPD in LUAD, we firstly analyzed the whole-genome/exome sequencing data obtained by Wu et 
al. in 85 patients with spirometry data available14. Of these, 18 cases (21.2%) were diagnosed as COPD, and 67 
cases (78.8%) were classified in non-COPD group. To determine if genomic differences existed between tumors 
from COPD and non-COPD group, we compared the mutational burden, spectrum and affected genes between 
Characteristics
Overall COPD Non-COPD
P-valueN = 272 n = 60 n = 212
Age (y, mean ± SD) 58.64 ± 10.84 64.32 57.03 <0.0001
Gender 0.0249
Male 149 41 108
Female 123 19 104
Smoking 0.0009
No 157 23 134
Yes 89 30 59
Unknown 26 7 19
WBC (×109/L) 7.28 ± 2.39 7.63 7.19 0.667†
Neutrophil (×109/L) 4.59 ± 2.05 4.9 4.5 0.262
Eosinophil (×109/L) 0.21 ± 0.21 0.27 0.2 0.067
Basophil (×109/L) 0.035 ± 0.019 0.036 0.034 0.678
Monocyte (×109/L) 0.56 ± 0.32 0.61 0.5 0.130
Lymphocyte (×109/L) 1.91 ± 0.65 1.83 1.93 0.361
Lymphocyte-Monocyte ratio 3.90 ± 1.70 3.51 4.01 0.045
CEA (ng/ml) 4.82 (0.33–1780) 39.48 10.8 0.337
CA125 (U/ml) 13.67 (2.04–526) 32.16 23.42 0.389
CA153 (U/ml) 13.15 (3.47–180.8) 15.88 18 0.252
NSE (ng/ml) 15.2 (8.5–63.0) 17.38 16.47 0.706
CYFRA21–1 (ng/ml) 2.7 (1.13–12.08) 3.25 3.02 0.594
FVC (%Pred) 97.68 ± 17.46 94.45 ± 20.97 98.60 ± 16.27 0.161
FEV1 (%Pred) 91.41 ± 20.30 71.64 ± 20.88 97.01 ± 16.28 <0.0001
FEV1/FVC 76.12 ± 10.82 60.17 ± 8.96 80.64 ± 5.91 <0.0001
FEV1 (value) 2.31 ± 0.65 1.82 ± 0.64 2.44 ± 058 <0.0001
Table1. Characteristics of 272 LUAD patients and their association with COPD status. †U-test.
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these two groups. Negative binomial regression in univariate analysis revealed that the number of missense 
mutation was much higher in COPD patients compared to non-COPD patients (Table 2, COPD median = 88.5 
Vs non-COPD median = 51, p = 0.021). Similarly, the number of nonsense mutation (Supplementary Table S1, 
COPD median = 8 vs non-COPD median = 4, p = 0.0358) and splice variant (COPD median = 2.5 vs non-COPD 
median = 2, p = 0.0371) was also significantly higher in COPD patients compared to non-COPD patients. Given 
the higher number of mutational burden among smokers and male patients in this study (Table 2) and previ-
ous studies15, 16, multivariable analysis with negative binomial regression was performed. After adjusting of age 
at diagnosis, gender and smoking status, no statistical difference in number of missense mutation was found 
between the COPD and non-COPD groups (Table 2), suggesting that mutational burden was not an independ-
ent factor associated with COPD status. We further performed the same analysis on the whole-exome sequenc-
ing data from the LUAD patients in The Cancer Genome Atlas (TCGA) cohort. Ninety-nine LUAD patients 
with spirometry data available were enrolled in this validation cohort. In contrasts to our cohort, most of these 
patients in TCGA cohort were from North America (detailed characteristics of these patients were summarized 
in Supplementary Table S2). Negative binomial regression in univariate analysis showed that no significant dif-
ference was observed in mutational burden between COPD and non-COPD group (Supplementary Table S3, 
COPD median = 195 vs non-COPD median = 203, p = 0.133) probably due to higher percentage of smokers in 
non-COPD group in TCGA cohort(64/75, 85.3%) compared to our cohort (23/62, 37.1%).
We further illustrated the characteristics of mutation in patients from TCGA and our cohort according to their 
COPD status as shown in Fig. 1A. Similar mutational spectra were observed between COPD and non-COPD 
groups in both cohorts. Specifically, C:G → A:T transversions were the most frequent somatic substitutions, 
which was reported predominately in cigarette smoker, whereas C:G → T:A transitions were the most common 
point mutations which were found in never-smokers16, 17.
As COPD increased the risk for the development of lung cancer, we continued to explore whether COPD 
could leave distinct mutational patterns in the genome of LUAD. As mutational catalogues from exomes could 
also be used to decipher mutational signature18, we thus compared the mutation signatures between COPD 
and non-COPD patients using the whole-exome sequencing data as described previously18. Two highly confi-
dent mutational signatures were extracted from each group, showing no significant difference between COPD 
and non-COPD group. The first highly correlated signature (Fig. 1B,C, signature 1 in our cohort and TCGA 
cohort, Pearson Correlation >0.95) was predominated by C > A mutations and associated with cigarette smok-
ing exposure. The second highly correlated signature (Pearson Correlation >0.91) was closely associated with 
over-activated member of APOBEC cytidinedeaminase17. As a validation, two similar mutation signatures were 
also generated from COPD and non-COPD group in TCGA cohort. Taken together, the mutational signature 
revealed that the tumors from LUAD patients with and without COPD exhibited similar mutational patterns.
Somatic alterations in LUAD patients with COPD. Several previous studies have demonstrated that 
mutation in EGFR was inversely associated with the presence of COPD in lung cancer19, 20. Although no signifi-
cant difference was found in mutational signature between COPD and non-COPD group, we continued to focus 
on the genetic alterations in individual genes between two groups. To increase the statistical power, somatic 
alterations obtained from targeted sequencing data of another 187 cases was also included in this analysis. As 
Variable
No. of patients 
(n = 85)
No. of missense mutation 
median(range)
Univariate analysis 
p value
Multivariate analysis 
p value
Age, year 0.765 0.897
 ≤65 59 48 (3–787)
 >65 26 80.5 (19–236)
Gender <0.0001 0.0002
 Male 52 92 (16–787)
 Female 33 34 (3–207)
Smoking <0.0001 0.0310
 Yes 33 126 (16–787)
 No 47 46 (3–262)
 NA 5 —
Stage
 I 18 39.5 (3–787) (reference) (reference)
 II 16 74.5 (20–262) 0.879 0.3340
 III 45 59 (16–690) 0.332 0.0940
 IV 6 50.5 (37–144) 0.43 0.6670
 NA —
COPD 0.0211 0.6560
 Yes 18 88.5 (19–690)
 No 67 51.0 (3–787)
Table2. Univariate and multivariate analysis with negative binomial regression comparing the mutation counts 
by variables in patients with lung adenocarcinoma (n = 85). NA, Not applicable.
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shown in Fig. 2, Fisher’s exact test analysis revealed that among the frequently mutated genes, mutations in EGFR 
were more enriched in non-COPD patients (25.0% in COPD Vs 39.6% in non-COPD, p = 0.047), while muta-
tions in LRP1B were more frequently observed in COPD (31.7% in COPD Vs 13.7% in non-COPD, p = 0.003). 
Consistent with previous study21, 22, COPD was not associated with KRAS mutation in our cohort (Fig. 2).
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Figure 1. Mutational patterns of LUAD with and without COPD. (A) Comparison of mutational types and 
frequencies between LUAD with or without COPD in this study (Guangzhou Medical University (GMU) 
cohort) as well as in TCGA cohort. Mutational Signatures of LUAD with or with COPD derived from GMU 
cohort (B) and TCGA cohort (C). Signatures were displayed according to the 96-substitution classification, with 
x-axes showed mutation types and y-axes showed trinucleotide frequency of each mutation type.
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To exclude the influence of smoking, we continued to compare the genetic alterations between COPD and 
non-COPD patients among smokers and non-smokers, respectively. The subgroup analysis revealed that muta-
tions in LRP1B were more frequently observed in COPD patients among non-smokers (21.7% in COPD Vs 8.2% 
in non-COPD, p = 0.06) and smokers (40% in COPD Vs 23.7% in non-COPD, p = 0.14) although the differences 
were not statistically significant largely due to the limited sample size in subgroup (Supplementary Fig. S1). This 
result suggested that mutation in LRP1B was closely correlated with COPD-associated lung cancer.
To validate these findings in an independent cohort, we analyzed the exomic sequencing data of tumors and 
normal control from the LUAD patients in TCGA cohort. However, as shown in Supplementary Fig. S2, there 
was no difference in mutational profile between COPD and non-COPD patients when we focused on the mutated 
genes.
Multivariable analysis of risk factors associated with the presence of COPD in LUAD patients. In 
the univariate analysis, we found the presence of COPD in LUAD patients was associated with older age at diagnosis, 
cigarette smoking and male sex, LMR and higher prevalence of somatic mutation in LRP1B, lower prevalence of 
mutation in EGFR.
To identify the independent risk factors associated with the presence of COPD in LUAD, we performed mul-
tivariable analysis with logistic regression using sex, age at diagnosis, smoking status, LMR, EGFR and LRP1B 
mutation as covariates. The result showed LRP1B mutation remained as an independent risk factor associated 
with COPD in LUAD even after adjustment of age, gender and smoking status (Table 3, HR = 2.33, 95%CI: 1.04–
5.21, p = 0.039). This result suggested that mutation in LRP1B might help distinguish between lung cancer in the 
presence and absence of COPD.
The association of COPD with overall survival of LUAD patients. To further investigate the asso-
ciation between COPD and overall survival in LUAD patients, we performed univariate analysis showing that 
the presence of COPD was not associated with overall survival of LUAD patients in our cohort (Supplementary 
Table S3). In contrast, gender, stage, preoperative LMR and levels of CA125 and CA153 were associated with 
worse overall survival in our cohort (Supplementary Table S4).
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18% LRP1B *
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Figure 2. Recurrent Somatic mutations and their associations with clinical parameters in LUAD patients 
with or without COPD. Recurrently mutated genes and the mutant frequencies in the primary tumors with or 
without COPD from GMU cohort were shown. Gender, smoking status, tumor stages and survival were listed 
at the bottom according to the samples, as well as mutation types. Asterisks indicate genes predicted to be 
significantly mutated between COPD and non-COPD group (P < 0.05, Fisher’s exact test).
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Discussion
COPD and lung cancer are both common pulmonary diseases, and epidemiological studies show that COPD 
represents an independent risk factor for lung cancer. Although LUAD patients with COPD displayed distinct 
clinical characteristics such as older age, male sex and cigarette smoking, it is unknown whether lung cancer 
patients with COPD harbor distinct genomic characteristics compared to those without COPD. In this study, we 
aimed to identify the somatic genetic alterations that might distinguish between LUAD patients with and without 
COPD. Our analysis of genomic sequencing data showed the high concordance in mutational burden and spec-
trum between the LUAD patients with and without COPD. Moreover, we also identified EGFR and LRP1B were 
mutated at different frequencies in COPD and non-COPD groups.
COPD is characterized by more excessive inflammation and oxidative stress response when compared with 
lung cancer. It is unknown that whether there was difference in the mutational profiling of the tumors arose from 
different tumor microenvironments. Mutational signature analysis in this study suggested that there was no spe-
cific mutation pattern during the development of lung cancer associated with COPD. The high concordance in 
the mutational burden and spectra further suggested the inflammatory milieu surrounding the tumors cells did 
not generate new mutations in LUAD patients. This notion was supported by the recent study which reported that 
epithelial-mesenchymal transition (EMT) was an independent mediator driving changes in the tumor immune 
microenvironment in LUAD, but not a surrogate for mutational burden23. In contrast, previous integrative anal-
ysis of DNA methylation and transcriptome profiling demonstrated that the presence of COPD was associated 
with changes of methylation and expression in genes involved in immune response in non-small cell lung cancer 
(NSCLC)24.
Despite the high concordance in mutational pattern and burden between COPD and non-COPD groups, we 
still found different frequencies of mutations in EGFR and LRP1B genes among LUAD patients with and without 
COPD. In fact, lower mutation rate of EGFR in lung cancer associated-COPD has been found in several studies19, 20. 
However, the higher prevalence of LRP1B mutation in LUAD associated-COPD was reported for the first time 
by analyzing the genomic sequencing data. LRP1B was reported as a putative tumor suppressor gene, encoding a 
new member of low density lipoprotein receptor. The dysregulation of this gene was associated with cell migra-
tion, chemoresistance and worse clinical outcome in cancer25, 26. LRP1B was also identified as a potential driver 
gene and its mutation was significantly associated with cigarette smoking in LUAD14, while our results indicated 
that LRP1B mutation was associated with COPD independent of cigarette smoking. Given that COPD is an inde-
pendent risk factor for lung cancer, this study suggested that early monitor of lung cancer should be performed in 
the patients with COPD. This finding also suggested that mutation in LRP1B could be a predictive biomarker that 
distinguished the LUAD patients in the presence and absence of COPD.
Meta-analysis demonstrated that the presence of COPD was associated with worse clinical outcome of lung 
cancer27. Even though we and other group demonstrated that lung cancer-associated with COPD preferentially 
harbored somatic mutations in a few genes, the tumors from COPD and non-COPD patients exhibited highly 
concordant genomic alterations, which might not explain the differences in clinical outcomes between these two 
groups.
We aimed to identify the genomic alterations in LUAD associated with COPD. Of note there were some lim-
itations to this study. First, there were dramatic differences between our cohort and the validation cohort. The 
prevalence of smoker in COPD group from our cohort was relatively lower compared with the TCGA cohort 
(56.6% Vs 87.5%), but was comparable to that (59.4%) in another constitutive cohort of lung cancer patients with 
COPD from Korean population19. This might suggest the different etiological factors associated with COPD in 
different ethnic populations. In fact, the prevalence of COPD in China was significantly associated with poor 
ventilation in the kitchen and exposure to biomass fuels in addition to cigarette smoking, elder age28. Second, 
in TCGA cohort, most LUAD patients (423/522, 81.0%) were excluded for subsequent analysis due to missing 
spirometry data. The limited number of sample size made it difficult to identify the variants associated with 
COPD unbiasedly. Last, COPD is a quite heterogeneous obstructive lung disease, and the presence of emphysema 
confers increased risk of lung cancer. However, in this retrospective study, COPD patients were defined by airflow 
obstruction on the spirometry according to the Global Initiative of Chronic Obstructive Lung Disease (GOLD) 
guidelines, by which we could not discriminate between emphysema and chronic bronchitis predominant phe-
notypes. Therefore, further investigation in a large cohort is warranted to validate the distinct prevalence of muta-
tions in EGFR and LRP1B among LUAD patients with COPD and clarify the impact of COPD on the survival of 
the patients with lung cancer.
All together, our integrative analysis of genomic sequencing data and clinicopathological information demon-
strated that the LUAD patients with and without COPD harbored highly concordant genomic characteristics. 
Lung cancer-associated COPD might represent a distinct subtype of lung cancer associated with distinct molec-
ular characteristics. Higher level of mutation in LRP1B and surrounded inflammatory microenvironment would 
be exploited as a therapeutic target and a diagnosis biomarker for LUAD patients with COPD.
Variable
COPD
Odds Ratio 95%CI p-value
Age 1.07 1.03–1.11 0.0004
Smoking, yes 2.56 1.16–5.85 0.022
LRP1B, mutated 2.33 1.04–5.21 0.039
Table 3. Multivariate analysis of patient characteristics associated with COPD.
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Materials and Methods
Patient information. This study has been approved by Institutional Review Board of the First Affiliated 
Hospital of Guangzhou Medical University (Approval Number 2013–20) and conducted in accordance with the 
Declaration of Helsinki Principles. Written informed consent was obtained from all participants. The inclusion 
and exclusion criteria for the patients and specimens were described previously14. Briefly, three hundred and thir-
ty-five LUAD patients whose tumors have been sequenced using whole-genome/exome or ultra targeted sequenc-
ing as previously were retrospectively analyzed. Of these, sixty-three patients who did not have the spirometry 
data available were excluded. Of the remaining 272 patients, whole genome or whole-exome sequencing was per-
formed on the primary tumors and paired normal tissues from 85 cases, and targeted sequencing of 51 selected 
genes was performed in an additional 187 cases. The clinical data including gender, age at diagnosis, smoking sta-
tus, TNM stage and spirometry data were extracted from electronic medical records. The COPD was diagnosed 
and classified according to the current Global Initiative of Chronic Obstructive Lung Disease (GOLD) guidelines. 
The LUAD patients with FEV1/FVC <70% (post-bronchodilator) were assigned to COPD group. Meanwhile, 99 
out of 522 LUAD patients (19.0%) from TCGA with spirometry data available were also included in this study as 
an independent validation cohort.
DNA sequencing data retrieval. The whole-genome/exome or targeted sequencing data of tumors and 
adjacent normal tissues from 272 LUAD patients and the clinical and demographic information were extracted 
from our previous study14 (All the sequencing data have been deposited at http://www.ebi.ac.uk/ega/).
DNA sequencing data of the tumors and normal controls and the corresponding clinical information from 
ninety-nine lung adenocarcinoma patients with spirometry data available in TCGA cohort were downloaded 
from gdac.broadinstitute.org.
Mutation signature analysis of LUAD exomes. Mutational signature analysis was performed as 
described previously14, 17, 18. In brief, mutational catalogues from the genomic sequencing data of primary tumors 
derived from our cohort (n = 85) and TCGA cohort (n = 99) were used to decipher the mutational signatures. 
Pearson’s correlation analysis was performed to compare signature patterns between COPD and non-COPD 
groups. And the affected mutational process was determined by comparing the extracted signatures with signa-
ture set identified previously17, 18 (http://cancer.sanger.ac.uk/cosmic/signatures).
Statistical analysis. Somatic variants from the LUAD patients in our cohort and TCGA cohort were 
extracted. Pearson’s Chi-square test or Fisher’s extract test were performed to compare the association between 
somatic alterations and clinical parameters such as gender, age, smoking and COPD status. Kaplan-Meier sur-
vival analysis was performed to estimate the overall survival with log rank test. The optimal cut-off value for 
Peripheral blood lymphocyte/monocyte ratio (LMR) was determined by Receiver-Operating Curve (ROC) anal-
ysis as described previously Multivariable analyses with logistic regression were carried out to determine the risk 
factor for the survival of LUAD with COPD. The p value < 0.05 is considered as statistically significant, and all the 
statistical tests were two-sided. The analyses were performed using SPSS16.0, R package and GraphPad Prism 6.0.
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